Gold prices edge higher on raised Fed rate cut hopes
In a recent Special Meeting held on Monday, Matinas BioPharma (NYSE:MTNB) Holdings, Inc. received shareholder approval on several significant proposals. The meeting, which was convened on April 4, 2025, saw a majority of shareholders casting their votes in favor of the company’s future plans. According to InvestingPro data, the micro-cap company, currently valued at $2.8 million, has seen its stock price decline by nearly 95% over the past year, highlighting the importance of these strategic decisions.
The first proposal, which passed with 88% approval, allows for the issuance of up to 16,894,212 shares of common stock upon the conversion of Series C Convertible Preferred Stock and the exercise of accompanying warrants. This issuance is in compliance with Section 713 of the NYSE American LLC Company Guide and may lead to a "Change of Control" as per the Guide’s definitions. InvestingPro analysis reveals the company holds more cash than debt on its balance sheet, with a healthy current ratio of 5.53, indicating strong short-term liquidity.
The second proposal, which garnered overwhelming support with 95% of the votes, ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for Matinas BioPharma for the fiscal year ending December 31, 2025.
Lastly, the third proposal approved with 90% of the votes was a contingency plan to adjourn the Special Meeting if necessary to solicit additional proxies in case there were not enough votes to approve the first two proposals.
The definitive proxy statement for the Special Meeting was filed with the Securities and Exchange Commission on March 3, 2025. Shareholders representing 52.47% of the common shares outstanding as of the February 10, 2025 record date were present at the meeting by proxy, ensuring a quorum and the legitimacy of the proceedings.
The approvals reflect shareholder confidence in the company’s strategic direction and financial governance. Matinas BioPharma Holdings, Inc., based in Bedminster, New Jersey, is listed on the NYSE American under the ticker symbol MTNB. The company specializes in pharmaceutical preparations and operates under the organization name 03 Life Sciences. InvestingPro analysis indicates the company currently has a Weak financial health score, with analysts not anticipating profitability this year. Subscribers to InvestingPro can access 8 additional key insights and a comprehensive Pro Research Report about MTNB’s financial outlook and market position.
This article is based on a press release statement from the Securities and Exchange Commission filing by Matinas BioPharma Holdings, Inc.
In other recent news, Matinas BioPharma Holdings, Inc. reported several significant changes within its Board of Directors. Eric Ende, the chairman, resigned due to other professional commitments, and his departure was confirmed not to be related to any disagreements with the company. Similarly, board member Herbert Conrad retired, with his resignation being effective from February 6, 2025. James S. Scibetta also stepped down from the board and his committee roles, citing professional commitments as the reason.
These board changes were disclosed in filings with the U.S. Securities and Exchange Commission, ensuring transparency and accuracy for shareholders. In a separate development, investment firm 111 Equity Group increased its ownership stake in Matinas BioPharma to 5.17%, indicating confidence in the company’s potential. The firm has been in discussions with Matinas’ management as part of the company’s ongoing strategic review. This review includes exploring options such as asset monetization and potential mergers to enhance shareholder value.
Matinas’ cash reserves remain substantial, with a reported amount of over $10 million, despite a significant workforce reduction. The company continues to navigate these changes while maintaining a focus on its strategic objectives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.